European Pharma Group Warned of Funding Gap
The European Federation of Pharmaceutical Industries and Associations flagged a lack of dedicated health funds in the EU.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Should the European Union increase long-term budget funding to support its pharmaceutical and biotech research?
Industry leaders have warned that the European Union lacks dedicated health funding in its upcoming long-term budget. This gap threatens the region's pharmaceutical competitiveness compared to the United States and China.
Why it matters
Experts argue that without targeted investment, pharmaceutical research in Europe will decline. This lack of support could directly result in fewer new drug treatments becoming available to European patients.
The European Commission has proposed a one-year extension of Supplementary Protection Certificates for certain medicines to address industry concerns. The total impact of this proposal on long-term regional drug development remains under investigation.
The players
European Federation of Pharmaceutical Industries and Associations
This trade association represents the research-based pharmaceutical industry operating within Europe.
Steffen Thirstrup
He is an expert who voiced concerns regarding the direct link between reduced research funding and the availability of new medicines.
European Commission
This is the executive branch of the European Union responsible for proposing legislation and implementing budget decisions.
The details
The European Federation of Pharmaceutical Industries and Associations raised the alarm during discussions in Gastein, Austria, noting that current fiscal plans prioritize other sectors. Steffen Thirstrup warned that this shortfall will likely stifle research investments and limit the variety of medicines reaching the European market.
Timeline
October 1, 2026: The warning regarding EU pharmaceutical funding was published.
Market Landscape
This dispute over research investment follows the established framework of the EU Supplementary Protection Certificate regulation. The European Commission's current proposal updates the application of this mechanism to mitigate broader concerns about regional pharmaceutical competitiveness.
If pharmaceutical research in Europe declines due to budget constraints, patients may experience delays in accessing next-generation treatments. A reduced pipeline of new drugs could ultimately limit the medical options available to consumers across the region.
The takeaway
Advocates argue that maintaining competitive pharmaceutical research requires consistent government backing within the long-term fiscal framework. Stakeholders emphasize that global leadership in medicine depends on active investment in local innovation pipelines.
Further reading
Explore more analysis regarding current medical policy in the /business/industry/healthcare/ section.
Source note: This article includes information reported by Euractiv DE.
Live Poll
Should the European Union increase long-term budget funding to support its pharmaceutical and biotech research?
